/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Vaccinex Inc Share Price Today: Live Updates & Key Insights

Vaccinex Inc share price today is $1.3211, up -61.37%. The stock opened at $1.94 against the previous close of $3.65, with an intraday high of $2 and low of $1.24.

Vaccinex Inc Share Price Chart

style
pb-0

Vaccinex Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Vaccinex Inc Share Price Performance

$1.3211 -0.6137(-61.37%) VCNX at 13 Mar 2026 03:43 PM Biotechnology
Lowest Today 1.24
Highest Today 2
Today’s Open 1.94
Prev. Close 3.65
52 Week High 13.02
52 Week Low 1.24
Day’s Range: Low 1.24 High 2
52-Week Range: Low 1.24 High 13.02
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -
3 year return -
5 year return -
10 year return -

Vaccinex Inc Institutional Holdings

Point72 Asset Management, L.P. 6.20

Armistice Capital, LLC 6.13

UBS Group AG 0.13

Fidelity Extended Market Index 0.12

Tower Research Capital LLC 0.07

Fidelity Series Total Market Index 0.04

Vanguard Institutional Extnd Mkt Idx Tr 0.03

State St US Extended Mkt Indx NL Cl C 0.00

Spartan Extended Market Index Pool E 0.00

Northern Trust Extended Eq Market Idx 0.00

NT Ext Equity Mkt Idx Fd - L 0.00

Group One Trading, LP 0.00

Advisor Group Holdings, Inc. 0.00

Spartan Total Market Index Pool E 0.00

Royal Bank of Canada 0.00

NT Ext Equity Mkt Idx Fd - NL 0.00

SSgA U.S. Total Market Index Strategy 0.00

Barclays PLC 0.00

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

Bank of America Corp 0.00

State St US Ttl Mkt Indx SL Cl I 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

BNYM Mellon SL Market Completion UC1 0.00

Northern Trust Wilshire 5000 0.00

Capital Advisors, Ltd. LLC 0.00

Morgan Stanley - Brokerage Accounts 0.00

Wells Fargo & Co 0.00

AIGH Capital Management, LLC 0.00

BNYM Mellon NSL Mkt Completion Fund Inst 0.00

Tacita Capital Inc. 0.00

Vaccinex Inc Market Status

Strong Buy: 1

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Vaccinex Inc Fundamentals

Market Cap 9.77 M

PB Ratio 7.3409

PE Ratio 0.4919

Enterprise Value 8.55 M

Total Assets 3.63 M

Volume 758951

Vaccinex Inc Company Financials

Annual Revenue FY23:620000 0.6M, FY22:100000 0.1M, FY21:900000 0.9M, FY20:50000 0.1M, FY19:523000 0.5M

Annual Profit FY23:null 0.0M, FY22:100000 0.1M, FY21:900000 0.9M, FY20:48000 0.0M, FY19:324000 0.3M

Annual Net worth FY23:-22012000 -22.0M, FY22:-19722000 -19.7M, FY21:-23232000 -23.2M, FY20:-29309000 -29.3M, FY19:-32015000 -32.0M

Quarterly Revenue Q3/2024:52000 0.1M, Q2/2024:232000 0.2M, Q1/2024:104000 0.1M, Q4/2023:0 0.0M, Q3/2023:20000 0.0M

Quarterly Profit Q3/2024:52000 0.1M, Q2/2024:-3632000 -3.6M, Q1/2024:77000 0.1M, Q4/2023:null 0.0M, Q3/2023:20000 0.0M

Quarterly Net worth Q3/2024:-5732000 -5.7M, Q2/2024:-5631000 -5.6M, Q1/2024:-3897000 -3.9M, Q4/2023:-3317000 -3.3M, Q3/2023:-4912000 -4.9M

About Vaccinex Inc & investment objective

Company Information Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Organisation Biotechnology

Employees 37

Industry Biotechnology

CEO Dr. Maurice Zauderer Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow